TIDMAZN

RNS Number : 4580B

AstraZeneca PLC

07 October 2015

ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA

AstraZeneca has announced the global completion of the divestment of Caprelsa(R) (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.

Genzyme made an upfront payment to AstraZeneca of $165 million to acquire the global rights to sell and develop Caprelsa, and will make further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities.

The divestment reinforces AstraZeneca's strategic focus on its three main therapy areas. As an asset divestment, the upfront receipt and any subsequent payments for the agreement will be reported in Other Operating Income in the Company's financial statements. The transaction does not impact AstraZeneca's financial guidance for 2015.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

 
 Media Enquiries 
                                                  +44 20 7604 
 Esra Erkal-Paler                   UK/Global      8030 
                                                  +44 20 7604 
 Vanessa Rhodes                     UK/Global      8037 
                                                  +44 20 7604 
 Ayesha Bharmal                     UK/Global      8034 
                                                  +44 20 7604 
 Karen Birmingham                   UK/Global      8120 
                                                  +46 8 553 260 
 Jacob Lund                         Sweden         20 
                                                  +1 302 885 
 Michele Meixell                    US             2677 
 Investor Enquiries 
 UK 
 Thomas Kudsk                       +44 20 7604 
  Larsen               Oncology      8199         +44 7818 524185 
                                    +44 20 7604 
 Eugenia Litz          RIA           8233         +44 7884 735627 
                                    +44 20 7604 
 Nick Stone            CVMD          8236         +44 7717 618834 
                                    +44 20 7604 
 Craig Marks           ING           8591         +44 7881 615764 
                                    +44 20 7604 
 Christer Gruvris                    8126         +44 7827 836825 
 US 
                       Oncology,    +1 301 398    +1 240 543 
 Lindsey Trickett       ING          5118          7970 
                                    +1 301 398    +1 301 398 
 Mitch Chan            Oncology      1849          1849 
                                    +1 301 398     +1 866 381 
 Dial / Toll-Free                    3251           7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

7 October 2015

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAEEKELKSFAF

(END) Dow Jones Newswires

October 07, 2015 02:00 ET (06:00 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.